Immune-related protein signature in serum stratify relapsed mantle cell lymphoma patients based on risk.

ABSTRACT:

Background

Response to modern treatment strategies, which combine cytotoxic compounds with immune stimulatory agents and targeted treatment is highly variable among MCL patients. Thus, providing prognostic and predictive markers for risk adapted therapy is warranted and molecular information that can help in patient stratification is a necessity. In relapsed MCL, biopsies are rarely available and molecular information from tumor tissue is often lacking. Today, the main tool to access risk is the MCL international prognostic index (MIPI), which does not include detailed biological information of relevance for different treatment options. To enable continuous monitoring of patients, non-invasive companion diagnostic tools are needed which can further reduce cost and patient distress

SUBMITTER: Lokhande L 

PROVIDER: S-EPMC7720632 | biostudies-literature | 2020 Dec

REPOSITORIES: biostudies-literature